INVESTORS & MEDIA

European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018

Dec 15, 2018


Additional Information

  • Atara Biotherapeutics and its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present tab-cel® efficacy and safety results in patients with EBV-associated leiomyosarcoma (EBV+ LMS) solid tumors.
  • The poster will be featured during the upcoming European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held December 13-16, 2018, in Geneva, Switzerland.
  • View press release
  • Details for the poster presentations are as follows:
    • Abstract 222 (Session 37): Efficacy and safety of tabelecleucel in patients with Epstein Barr Virus-associated leiomyosarcomas (EBV+ LMS)
      Oral Presentation Date and Time: Saturday, December 15, 2018 at 8:05 a.m.
      Location: Room A, Palexpo Exhibition Centre, Geneva, Switzerland
      Authors:L.S. Kurlander, A. Srinivasan, A. Ghobadi, S. Suser, E. Doubrovina, F. Boulad, L. Mascarenhas, M. Laquaglia, A. Price, G. Behr, B. Shulkin, A. Sudhindra, Y. Wei, M. Hiremath, W. Navarro, R. O'Reilly, S. Prockop
      Affiliations: Weill Cornell New York Presbyterian Hospital, St. Jude Children's Research Hospital, Washington University School of Medicine, Children’s Hospital of Los Angeles, Atara Biotherapeutics, Memorial Sloan Kettering Cancer Center